Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology 2016-2026
Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2016 to 2026
The Definitive Resource for Structuring and Benchmarking Shared Commercialization Partnerships
The Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology 2016–2026 report provides the most comprehensive analysis available of co-commercialization strategies across the life sciences industry. Featuring 384 detailed deal records and links to publicly available contracts where filed, this fully revised and updated report gives you an unmatched look inside the terms, structures, and strategies behind the industry's most impactful partnerships.
Whether you're negotiating a new alliance or benchmarking existing agreements, this report gives you the data-driven insights you need to craft smarter, stronger, and more profitable deals.
Free report sample
What You’ll Gain
✔ Access 384 Real-World Deals – Get the details on deal structure, revenue sharing, territory splits, and commercialization responsibilities, with links to online contract documents where available.
✔ Understand Winning Structures – See how biopharma leaders split promotional duties, allocate rights, and manage exclusivity across co-promotion and co-marketing agreements.
✔ Negotiate with Confidence – Leverage detailed financial data, including payment terms, to understand what’s standard—and what’s possible.
✔ Learn from the Leaders – Examine how top players like Pfizer, Novartis and AstraZeneca approach co-commercialization.
✔ Access Real Contracts – Where available, review actual SEC-filed agreements to understand deal mechanics that press releases and databases don’t reveal.
✔ Stay Ahead of Market Trends – Track activity including trends by year, therapy area, technology type, and company A–Z.
Inside the Report – Chapter Overview
Chapter 1: Introduction
An orientation to the structure, purpose, and use of the report.
Chapter 2: Co-promotion and Co-marketing Trends
Covers key industry trends, growth in activity, and strategic rationale for shared commercialization models.
Chapter 3: Deal Structures and Terms
Explains how companies structure these partnerships—including revenue splits, territories, exclusivity, responsibilities, and duration.
Chapter 4: Top Deals by Value
A curated overview of high-value deals with direct links to online records and available SEC-filed contracts.
Chapter 5: Top 25 Most Active Dealmakers
Profiles of the most prolific companies in co-commercialization, each linked to their deal records and available contract documents.
Chapter 6: Deal Analysis by Company, Therapy & Tech
An in-depth review of all co-promotion and co-marketing deals signed since 2016, categorized by company A–Z, therapeutic area, technology type, and contract availability.
Deal Directory
A complete deal listng, each linked to a detailed record in the Current Agreements database, with direct access to contract documents where available.
What’s Included
-
Industry trends in co-promotion and co-marketing (2016–2026)
-
Overview of deal structures and revenue models
-
Analysis of top deals and dealmakers
-
Directory of all deals by company, therapy area, and technology
-
Access to real contract documents (where publicly available)
-
Numerous tables and figures illustrating activity across the industry
Who Should Use This Report?
✅ Business Development & Licensing Teams – Evaluate deal structures and identify ideal partners.
✅ Commercial Strategy & Operations – Plan smarter co-launches and regional strategies.
✅ Legal & Contracts Teams – Benchmark clauses and strengthen negotiation positions with real contract language.
✅ C-Level Executives & Investors – Assess monetization strategies and partnership dynamics in commercial-stage assets.
Due Diligence Made Easy: What You’ll Learn from Contracts
By reviewing actual deal agreements, you can evaluate key aspects such as:
-
What rights are granted or optioned?
-
How is revenue shared and audited?
-
What exclusivity and territory provisions are included?
-
Who handles commercialization, manufacturing, and supply?
-
What is the term and how is termination managed?
-
How are disputes, confidentiality, and publication handled?
-
Which legal jurisdiction is used?
-
Are sublicensing and subcontracting allowed?
-
Which clauses are standardized, and which vary across partners?
Why This Report Matters
Co-promotion and co-marketing strategies have become vital for maximizing commercial potential, especially in competitive or specialty-driven markets. This report delivers critical intelligence on how industry leaders are structuring these deals—giving you a clear path to negotiate better terms, avoid common pitfalls, and select the right partners.
Get ahead of your next deal. Explore the data. Learn from the contracts. Make better decisions.
✔ Access Real-World Deals – Get the details on deal structure, revenue sharing, territory splits, and commercialization responsibilities, with links to online contract documents where available.
✔ Understand Winning Structures – See how biopharma leaders split promotional duties, allocate rights, and manage exclusivity across co-promotion and co-marketing agreements.
✔ Negotiate with Confidence – Leverage detailed financial data, including payment terms, to understand what’s standard—and what’s possible.
✔ Learn from the Leaders – Examine how top players like Pfizer, Novartis and AstraZeneca approach co-commercialization.
✔ Access Real Contracts – Where available, review actual SEC-filed agreements to understand deal mechanics that press releases and databases don’t reveal.
✔ Stay Ahead of Market Trends – Track activity including trends by year, therapy area, technology type, and company A–Z.
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in co-promotion and co-marketing dealmaking
2.1. Introduction
2.2. Definition of co-promotion and co-marketing deals
2.3. Trends in co-promotion and co-marketing deals since 2016
2.3.1. Co-promotion and co-marketing dealmaking by year, 2016-2026
2.3.2. Co-promotion and co-marketing dealmaking by phase of development, 2016-2026
2.3.3. Co-promotion and co-marketing dealmaking by industry sector, 2016-2026
2.3.4. Co-promotion and co-marketing dealmaking by therapy area, 2016-2026
2.3.5. Co-promotion and co-marketing dealmaking by technology type, 2016-2026
2.3.6. Co-promotion and co-marketing dealmaking by most active company, 2016-2026
2.4. Reasons for entering into co-promotion and co-marketing partnering deals
2.5. The future of co-promotion and co-marketing deals
Chapter 3 – Overview of co-promotion and co-marketing deal structure
3.1. Introduction
3.2. Co-promotion and co-marketing agreement structure
Chapter 4 – Leading co-promotion and co-marketing deals
4.1. Introduction
4.2. Top co-promotion and co-marketing deals by value
Chapter 5 – Top 25 most active co-promotion and co-marketing dealmakers
5.1. Introduction
5.2. Top 25 most active co-promotion and co-marketing dealmakers
Chapter 6 – Co-promotion and co-marketing deals including contracts directory
6.1. Introduction
6.2. Co-promotion and co-marketing deals with contracts 2016-2026
Deal directory
Deal directory – Co-promotion and co-marketing dealmaking by companies A-Z
Deal directory – Co-promotion and co-marketing dealmaking by therapy area
Deal directory – Co-promotion and co-marketing dealmaking by technology type
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Definition of co-promotion and co-marketing
Figure 2: Trends in co-promotion and co-marketing deal announcements, 2016-2026
Figure 3: Co-promotion and co-marketing deals signed at each phase of development, 2016-2026
Figure 4: Co-promotion and co-marketing deals by industry sector, 2016-2026
Figure 5: Co-promotion and co-marketing deals by therapy area, 2016-2026
Figure 6: Co-promotion and co-marketing deals by technology type, 2016-2026
Figure 7: Top 25 most active co-promotion and co-marketing dealmakers, 2016-2026
Figure 8: Top co-promotion and co-marketing deals by value, 2016-2026
Figure 9: Most active co-promotion and co-marketing dealmakers, 2016-2026
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $7,995: company (unencrypted file)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Delivery Deadline
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Biopharma Research Ltd based in County Durham, United Kingdom. We have been trading successfully online since 2012 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
About Current Partnering
A definitive, evidence-based approach to dealmaking intelligence
Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.
Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.
All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.
Our methodology
Built on a continuously updated proprietary database
All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.
Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.
Comprehensive and verifiable data sourcing
Deal data is sourced from publicly available industry disclosures, including:
- Company press releases and announcements
- SEC filings and equivalent regulatory disclosures
- Company and investor presentations
- Conference materials and company websites
All sources are captured and referenced, enabling full transparency and user verification.
Broad coverage across deal types and structures
Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:
- Licensing and co-development
- Research and collaborative R&D
- Manufacturing, supply, and distribution
- Commercialisation and co-promotion
- Equity investments, joint ventures, and asset transactions
- Options, royalties, and financing agreements
This breadth ensures a complete view of how partnerships are structured across the life sciences sector.
Structured, standardised analysis
Every deal is analysed using a consistent framework, capturing (where disclosed):
- Financial terms — including upfront payments, milestones, and royalties
- Rights allocation — development, manufacturing, and commercialization responsibilities
- Deal structure — exclusivity, territorial scope, and agreement type
- Contractual provisions — clauses defining risk, control, and value-sharing
Each deal record is fully categorised, including data fields such as:
- Therapy area and technology type
- Stage of development
- Asset type and deal components
- Geographic scope and exclusivity
- Source documentation, including press releases and SEC filings
Financial normalisation for comparability
All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.
Contract-level insight
Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.
This enables users to understand:
- How financial mechanisms are defined and triggered
- How responsibilities are operationalised between parties
- How flexibility, risk, and control are allocated within agreements
Designed for real-world application
Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:
- Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
- Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
- Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight
Common use cases include:
- Benchmarking comparable transactions
- Supporting valuation and deal structuring
- Preparing for negotiations
- Evaluating potential partners
- Informing internal strategy with real-world evidence
A trusted industry reference
With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.
By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.
